Published 5 months ago

FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR

The U.S. FDA has approved Casgevy, the country's first gene-editing treatment, for sickle cell disease patients aged 12 and older.
Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR technology to edit genes and treat the disease.
Analysts raise concerns about the high cost, complexity, and limited availability of the treatment.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

The Guardian

US regulators approve two gene therapies for sickle cell disease

Blood disorder that can lead to premature death affects estimated 100,000 people in the United States, most of whom are Black

5 months ago·London, United Kingdom

Read Full Article

CTV News

U.S. FDA approves two gene therapies for sickle cell disease

The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

5 months ago·Canada

Read Full Article

Reuters

US approves two gene therapies for sickle cell disease

The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio .

5 months ago·United Kingdom

Read Full Article

Associated Press News

Two gene therapies for sickle cell disease approved in US

Regulators on Friday approved two gene therapies for sickle cell disease that doctors hope can cure the painful, inherited blood disorder that afflicts

5 months ago·United States

Read Full Article